Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia

@article{Gu2010LowDO,
  title={Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia},
  author={Liu-fang Gu and Wang-gang Zhang and Fangxia Wang and Xing-mei Cao and Yin-xia Chen and Aili He and Jie Liu and Xiao-rong Ma},
  journal={Journal of Cancer Research and Clinical Oncology},
  year={2010},
  volume={137},
  pages={997-1003}
}
BackgroundTo explore the effect of low dose of homoharringtonine (HHT) and cytarabine (Ara-c) combined with granulocyte colony-stimulating factor (G-CSF) priming (HAG regimen) on relapsed or refractory acute myeloid leukemia (AML).MethodsSixty-seven patients with relapsed or refractory acute myeloid leukemia (AML) were enrolled. All the patients were treated with HAG regimen (HHT 1.5 mg/m2/day, 1–14d; Ara-C 7.5 mg/m2/12 h, 1–14d; G-CSF 150 μg/m2/day, according to the counting of the peripheral… 

Figures and Tables from this paper

Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time?
TLDR
Investigation of a combination of homoharringtonine (HHT), aclarubicine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (CHAG) in treating 36 patients with relapsed or refractory acute myeloid leukemia (AML) is encouraging, with an excellent response rate that exceeds the expected 17 – 60% response rate for conventional therapies used in this setting.
Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia
TLDR
There were significant correlations of OS with age, initial karyotype, performance status and gene mutations (NPM1,FLT-ITD and DNMT3A) at diagnosis and to the date of the last follow-up.
Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china
TLDR
The HAG regimen, a combination of low-dose HHT, Ara-c and granulocyte colony stimulating factor (G-CSF) priming, has been used to treat patients with relapsed/refractory and hypocellular AML and high-risk MDS, and has achieved a high response rate and demonstrated a good tolerability.
HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants
TLDR
The HAG regimen is an effective and safe regimen for the treatment of AML and MDS, and appears to be more effective and better tolerated than intensive chemotherapy.
Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia
TLDR
The homoharringtonine-based regimen achieved excellent EFS and alleviated hematologic toxicity for children aged younger than 2 years with de novo AML compared with the anthracycline- based regimen.
Effect of Homoharringtonine as a Combined Regimen for Acute Myeloid Leukemia
TLDR
Data outcomes of various combinations of HHT in combination with other chemotherapeutic agents for AML with or without genetic mutation specification exhibit that HHT has promising results in the treatment of AML which may lead to its approval in the upcoming years.
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen
TLDR
A case in which relapsed/refractory ETP-ALL was successfully salvaged by venetoclax plus HAG regimen is reported, and CR was still maintained at now 5 months after HSCT.
...
1
2
3
...

References

SHOWING 1-10 OF 48 REFERENCES
Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: A Multicenter Study of 112 Chinese Patients
TLDR
The CAG regimen seems promising, with acceptable toxicity, for the treatment of various categories of poor-prognosis AML and MDS-RAEBt and nonhematologic toxicities were not observed in this study.
Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
TLDR
Although this is a preliminary study, the CAG combination seems promising for the treatment of relapsed AML, with its low toxicity contributing to a higher quality of life for the patient.
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
TLDR
The dose of HHT 4 mg/m2 for 7 days by continuous infusion in combination with cytarabine is safe for patients with AML; and this combination is appropriate for a phase II evaluation.
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
TLDR
Homoharringtonine produced hematologic remissions in the majority of patients with advanced chronic-phase CML and Cytogenetic response occurred in some patients without an association with myelosuppression, and these responses may be prolonged.
Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia
TLDR
It is concluded that homoharringtonine, at the dose schedule investigated, has definite but low antileukemic efficacy and the role of such therapy in myeloproliferative disorders, especially chronic myelogenous leukemia, deserves consideration.
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients
TLDR
The FLAD regimen proved to be an effective and well-tolerated treatment, with acceptable toxicity in this group of high-risk patients, with a better response rate in the subgroup of relapsed patients, compared to patients treated for refractory disease.
Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia
TLDR
The data suggest that the Mito-FLAG protocol is feasible and can be safely performed with both schedules of Ara-C, and the regimens have shown high efficacy and acceptable toxicity in patients with relapsed or refractory AML.
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
TLDR
Compared to the previous trial (AML-MDS Study 01-92), the CR rate in all patients, as well as CR rate, overall survival, and relapse-free survival in patients >60 years have significantly been improved.
...
1
2
3
4
5
...